Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Michael Fox Foundation for Parkinson's Research (MJFF) has selected Epitomics to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties.
Subscribe to our email newsletter
As per the terms of a special arrangement, the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts.
Epitomics said that the antibodies are expected to be available to Parkinson’s researchers in academic/nonprofit and industry labs on a worldwide basis.
Epitomics CEO Guo-Liang Yu said that after a successful project to develop these LRRK2 antibodies, they were very pleased that MJFF has chosen Epitomics to now distribute these important antibodies to the research community going forward.
“We are happy to support this important area of research and lend a hand in helping researchers develop LRRK2 based therapies,” Yu said.
MJFF research programs associate research director Mark Frasier said LRRK2 antibodies are critical to help move Parkinson’s forward.
“The three clones chosen for initial release were identified based on several months of testing by our large network of PD researchers,” Frasier said.
“Epitomics has been a great partner and we are excited that they will continue to help MJFF remove barriers to developing Parkinson’s therapies.”